METABOLIC SURGERY IN CORRECTION OF FATTY LIVER DISEASE
https://doi.org/10.24884/0042-4625-2017-176-1-34-41
Abstract
The article presents the results of treatment of 68 patients who underwent laparoscopic sleeve gastric resection (LSG) and laparoscopic gastric bypass (LGB) at the period from 2014 to 2015. The efficacy of operations on the course of nonalcoholic fatty liver disease (NAFLD) was estimated. There were performed a liver biopsy and histological studies with determination of histological activity index, the rate of severity of fibrosis according R. G. Knodell scale and METAVIR system, nature and degree of manifestation of steatosis of hepatocytes and intrahepatic cholestasis. NAS activity scale was used to evaluate morphological changes. The results of 1,5-year follow-up study were assessed in dynamics. Fibro Test results were in the range from 0 to 1 depending of fibrosis severity using METAVIR system (from F0 to F4), Knodell and Ishak scales. It was stated that there was an improvement of histological and functional findings in cases of hepatic steatosis, inflammation and fibrosis. All the patients (100%) initially had the signs of NAFLD and 12 patients (22,6%) - fibrosis. The complete regression of NAFLD was noted in 43(81,1%) cases and signs of previous fibrosis were smoothed over in 6 patients (41%). Liver function tests have deteriorated at 6-month period, but tests improved to normal rates at the end of 1-year period. The bariatric surgeries are effective methods of NAFLD treatment and Fibro Test is non-invasive and reliable method of liver state assessment.
About the Authors
M. B. Fishman
I. P.Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
V. E. Karev
Research Institute of Children Infections
Russian Federation
Russian Federation
V. Yan
I. P.Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
D. A. Sokolova
I. P.Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
A. I. Mitsinskaya
I. P.Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
M. A. Mitsinskiy
I. P.Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
References
1. ВОЗ. Информационный бюллетень № 311 от января 2015 г. Источник: http://www.who.int/mediacentre/factsheets/fs311/ru.
2. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования наблюдения DIREGL 01903) // Рос. журн. гастроэнтерол. гепатол. колопроктол. 2014. Т. 24, № 4. С. 32-38.
3. Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени (методические рекомендации). М.: ООО «Издательский дом «М-Вести», 2009. 20 с.
4. Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и др. Диагностика и лечение НАЖБП / Под ред. В. Т. Ивашкина. М.: РОПИП, 2015. 38 с.
5. Павлов Ч. С., Коновалова О. Н., Ивашкин В. Т. и др. Сфера клинического применения неинвазивных методов оценки фиброза печени: результаты собственных исследований в многопрофильном стационаре // Клин. мед. 2009. Т. 87, № 11. С. 40-44.
6. Седов С. М., Фишман М. Б. Лапароскопическая хирургия ожирения. Практическое руководство (Атлас). СПб.: Издательство Седов В. М., Фишман М. Б., 2009, 192 с.
7. Akbar D. H., Kwatner A. H. Non-alcoholic fatty liver disease in saudi type 2 diabetic subjects. who attended a medical outpatient clinic: prevalance and genera characteristic-observations // Diabetes Care. 2003. Vol. 26. P. 3351-3352.
8. Bedossa P. Current histological classification of NAFLD: strength and limitations // Hepatol. Int. 2013. Vol. 7. Suppl. 2. P. 765-770.
9. Bedossa P., Poynard T. The METAVIR cooperative study group. An algorithm for the granding of activity in chronic hepatitis С // Hepatology. 1996. Vol. 24. P. 289-293.
10. Browning J. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity // Hepatology. 2004. Vol. 40. P. 1387-1395.
11. Buchwald H., Danette M. Oien. Metabolic/bariatric surgery worldwide 2011 // Obes. Surg. 2013. Vol. 23 (Issue 4). P. 427-436.
12. Champion J. K., Hunt T., DeLisle N. Laparoscopic vertical banded gastroplasty and Roux-en-Y gastric bypass in morbid obesity // Obes. Surg. 1999. Vol. 9. P. 123.
13. Clark J. M. The prevalence and etiology of elevated aminotransferase levels in the United States // Am. J. Gastroenterol. 2003. Vol. 98. P. 960-967.
14. Dixon J. B., Bhathal P. S., O’Brien P. E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese // Gastroenterology. 2001. Vol. 121. P. 91-100.
15. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Draft Statement // Obes. Surg. 1991. Vol. 1. P. 257-265.
16. Halfon P., Munteanu M. Poynard T. FibroTest-ActiTest as a noninvasive marker of liver fibrosis // Gastroenterol. Clin. Biol. 2008. Vol. 32, № 6. P. 22-39.
17. Kleiner D. E., Brunt E. M., Van Natta M. et al. Clinical research network. Design and validation of histological scoring system for nonalcoholic fatty liver disease // Hepatology. 2005. № 41. P. 1313-1321.
18. Knodell R. G., Ishak K. G., Black W. C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis // Hepatology. 1981. Vol. 1, № 5. P. 431-435.
19. Martínez S. M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis // Hepatology. 2011. Vol. 53, № 1. P. 325-335.
20. Masarone M., Frederico S., Abenavoli L. Persico M. Nonalcoholic fatty liver. Epidemiology and natural history // Rev. Recetn. Clin. Trials. 2014. Vol. 9, № 3. P. 126-133.
21. Mc Cullough A. J. The epidemiology and risk factors of NASH // Hepatology. 2013. Vol. 58, № 5. P. 1644-1654.
22. Neovius M., Narbro K., Keating C. et al. Health care use during 20 years following bariatric surgery // JAMA. 2012. Vol. 308. P. 1132-1141.
23. Pavlov C. S., Casazza G., Nikolova D. et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease // Cochrane Database of Systematic Reviews 2015, Issue 1. Art. №.: CD010542. DOI: 10.1002/14651858. CD010542.pub2.
24. Poynard M. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update // Gastroenterol. Clin. Biol. 2008. Vol. 32. P. 8-21.
25. Ratziu V., Bellentani S., Cortez-Pinto H. et al. A position statement on NAFLD/NASH based on the EASL 2009. Special Conference // J. Hepatol. 2010. Vol. 53. P. 372-384.
26. Schauer P. R., Ikramuddin S., Hamad G. et al. Laparoscopic gastric bypass surgery: current technique // J. Laparoendoscop. Adv. Surg. Techn. 2003. Vol. 13, № 4. P. 229-239.
27. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non alcoholic fatty liver disease and non alcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. 2011. Vol. 24. P. 274-285.
28. Wanless I. R., Lentz J. S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors // Hepatology. 1990. Vol. 12, № 5. P. 1106-1110.
29. WHO. Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity (Geneva, 3-5 June, 1997). Geneva: WHO.
30. WHO Global NCD InfoBase, WHO global comparable estimates [online database]. Geneva, WHO. 2005 http: // www.who.int/ ncd_surveillance, infobase/web/InfoBaseCommon.
31. WHO, Regional Office. Под редакцией Branca F., Nikogosian H., Lobstein T. / Проблема ожирения в Европейской регионе ВОЗ и стратегия ее решения. Резюме // Copenhagen, Denmark, 2007. P. 71. http: // www.euro.who.int/pubrequest.
32. Wiernsperger N. Treatment strategies for fatty liver diseases // Rev. Recent. Clin. Trials. 2014. Vol. 9, № 3. P. 185-194.
33. Williams C. D., Stengel J., Asike M. I. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. 2011. Vol. 140. P. 124-131.
34. World Gastroenterology Organisation Global Guidelines. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (WGO Global Guidelines NAFLD/NASH), June 2012.
Review
For citations:
Fishman M.B., Karev V.E., Yan V., Sokolova D.A., Mitsinskaya A.I., Mitsinskiy M.A. METABOLIC SURGERY IN CORRECTION OF FATTY LIVER DISEASE. Grekov's Bulletin of Surgery. 2017;176(1):34-41. (In Russ.) https://doi.org/10.24884/0042-4625-2017-176-1-34-41
Views:
498
Email this article 